USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARUNA BIOMEDICAL, INC.
Address:
RHODES CENTER, UGA
ATHENS, GA
Phone:
(706) 542-9191
URL:
EIN:
155089916
DUNS:
170950476
Number of Employees:
7
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,011,175.00 3

Award List:

Adhesion Signature-Based, Label-Free Isolation of Pluripotent Stem Cell Derived N

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$706,226.00
Agency:
HHS
Principal Investigator:
Jamie M. Chilton – 706-542-9191
Abstract:
DESCRIPTION (provided by applicant): Currently, up to one billion people worldwide suffer from disabling neurodegenerative disorders, including traumatic injuries, stroke and diseases of the CNS such as Alzheimer's and Parkinson's disease (PD). As the number of afflicted individuals… More

Developmental Neurotox Assay Using Scalable Neupons and Astrocytes in High Content Imaging

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$79,993.00
Agency:
EPA
Principal Investigator:
Steven Stice – 706-583-0071
Abstract:
The objective of this proposed project and the EPA Computational Toxicology program’s goals are aligned in assessing chemicals for potential risk to human health and the environment through the use of more representative multicellular human developmental neurotoxicology assays. ArunA Biomedical… More

Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiat

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$224,956.00
Agency:
HHS
Principal Investigator:
Jamie M. Chilton – 706-542-4941
Abstract:
SUMMARY The overarching objective of this Phase I project is to determine the feasibility of developing both focused and broad toxicity metabolomic assays for three neural development associated windows of susceptibility (WOS) for human development. Epidemiological and laboratory studies have… More